{"entity":{"id":"imid","kind":"term","name":"Immunomodulatory drugs (IMiDs) and CELMoDs","aka":["IMiD","IMiDs","immunomodulatory drugs","immunomodulatory agents","immunomodulatory imide drugs","CELMoD","CELMoDs","cereblon modulators","cereblon E3 ligase modulators","IKZF1/3 degradation","cereblon modulator","immunomodulatory drug"],"tldr":"Thalidomide and its descendants lenalidomide and pomalidomide, which hijack a cellular waste-disposal tag (cereblon) to destroy two proteins myeloma cells depend on, while also revving up T and NK cells. CELMoDs such as iberdomide and mezigdomide bind cereblon more tightly and work after lenalidomide fails; clots, low blood counts and birth defects are class risks.","summary":"Thalidomide's return from the 1960s disaster as a myeloma drug (1999) and the discovery that it acts as a molecular glue degrader of IKZF1/3 via cereblon founded the whole field of targeted protein degradation. Lenalidomide is in nearly every myeloma induction and maintenance regimen and treats del(5q) MDS and some lymphomas; pomalidomide follows lenalidomide failure. CELMoDs (iberdomide, mezigdomide) bind cereblon more tightly and are active in lenalidomide-refractory disease (EXCALIBER). Class effects are cytopenias, thrombosis (prophylaxis required), rash, and secondary cancers; teratogenicity mandates pregnancy-prevention programmes.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Immunomodulatory_imide_drug","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Immunomodulatory_imide_drug"}],"tags":[],"related":["vrd","proteasome-inhibitor","vte","mds"],"cancers":["multiple-myeloma"],"sections":["targeted-therapy"],"technologies":["molecular-glue-platforms","protac-degrader"],"targets":[],"drugs":["lenalidomide","pomalidomide","thalidomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Treatment jargon"},"route":"/terms/imid/","neighbours":{"term":[{"id":"proteasome-inhibitor","kind":"term","name":"Proteasome inhibitor (bortezomib, carfilzomib, ixazomib)","route":"/terms/proteasome-inhibitor/"},{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/"},{"id":"vrd","kind":"term","name":"VRd and Dara-VRd (myeloma induction regimens)","route":"/terms/vrd/"}],"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/"},{"id":"myeloma-transplant-ineligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-ineligible","route":"/cancers/myeloma-transplant-ineligible/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"drug":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"},{"id":"thalidomide","kind":"drug","name":"Thalidomide","route":"/drugs/thalidomide/"}]}}